Logo image of STTK

SHATTUCK LABS INC (STTK) Stock Fundamental Analysis

NASDAQ:STTK - US82024L1035 - Common Stock

1.025 USD
+0.03 (+3.54%)
Last: 8/26/2025, 1:59:10 PM
Fundamental Rating

2

Overall STTK gets a fundamental rating of 2 out of 10. We evaluated STTK against 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for STTK as it has an excellent financial health rating, but there are worries on the profitability. STTK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

STTK had negative earnings in the past year.
STTK had a negative operating cash flow in the past year.
In the past 5 years STTK always reported negative net income.
STTK had a negative operating cash flow in each of the past 5 years.
STTK Yearly Net Income VS EBIT VS OCF VS FCFSTTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of STTK (-95.56%) is worse than 74.77% of its industry peers.
The Return On Equity of STTK (-107.88%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -95.56%
ROE -107.88%
ROIC N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
STTK Yearly ROA, ROE, ROICSTTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

STTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STTK Yearly Profit, Operating, Gross MarginsSTTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
STTK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for STTK has been increased compared to 5 years ago.
There is no outstanding debt for STTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STTK Yearly Shares OutstandingSTTK Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STTK Yearly Total Debt VS Total AssetsSTTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -7.35, we must say that STTK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.35, STTK is doing worse than 66.36% of the companies in the same industry.
There is no outstanding debt for STTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.35
ROIC/WACCN/A
WACC9.72%
STTK Yearly LT Debt VS Equity VS FCFSTTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

STTK has a Current Ratio of 10.25. This indicates that STTK is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of STTK (10.25) is better than 81.72% of its industry peers.
STTK has a Quick Ratio of 10.25. This indicates that STTK is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.25, STTK belongs to the best of the industry, outperforming 81.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.25
Quick Ratio 10.25
STTK Yearly Current Assets VS Current LiabilitesSTTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

STTK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.59%, which is quite impressive.
Looking at the last year, STTK shows a very negative growth in Revenue. The Revenue has decreased by -27.40% in the last year.
The Revenue for STTK have been decreasing by -10.37% on average. This is quite bad
EPS 1Y (TTM)34.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, STTK will show a small growth in Earnings Per Share. The EPS will grow by 6.18% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y37.23%
EPS Next 2Y22.85%
EPS Next 3Y10.01%
EPS Next 5Y6.18%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
STTK Yearly Revenue VS EstimatesSTTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2031 100M 200M 300M 400M
STTK Yearly EPS VS EstimatesSTTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STTK. In the last year negative earnings were reported.
Also next year STTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STTK Price Earnings VS Forward Price EarningsSTTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STTK Per share dataSTTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.85%
EPS Next 3Y10.01%

More info and screens

0

5. Dividend

5.1 Amount

STTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SHATTUCK LABS INC

NASDAQ:STTK (8/26/2025, 1:59:10 PM)

1.025

+0.03 (+3.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners60.14%
Inst Owner Change-8.29%
Ins Owners1.8%
Ins Owner Change0%
Market Cap49.10M
Analysts78.18
Price Target1.49 (45.37%)
Short Float %1.05%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.92%
Min EPS beat(2)3.96%
Max EPS beat(2)5.88%
EPS beat(4)3
Avg EPS beat(4)4.66%
Min EPS beat(4)-13.57%
Max EPS beat(4)22.37%
EPS beat(8)6
Avg EPS beat(8)5.55%
EPS beat(12)10
Avg EPS beat(12)7.91%
EPS beat(16)12
Avg EPS beat(16)14.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40.65%
PT rev (3m)-40.65%
EPS NQ rev (1m)28.43%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)10.41%
EPS NY rev (3m)4.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.38
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.06
BVpS1.19
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.56%
ROE -107.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.12%
Cap/Sales 1.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.25
Quick Ratio 10.25
Altman-Z -7.35
F-Score6
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)129.93%
Cap/Depr(5y)216.43%
Cap/Sales(3y)603.92%
Cap/Sales(5y)369.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y37.23%
EPS Next 2Y22.85%
EPS Next 3Y10.01%
EPS Next 5Y6.18%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.66%
EBIT Next 3Y1.34%
EBIT Next 5Y-5.63%
FCF growth 1Y43.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.37%
OCF growth 3YN/A
OCF growth 5YN/A